Doctor Agata Tyminska

Medical University of Warsaw, Warsaw (Poland)

Membership: FESC Member

Contributor content

Presentation

Association of galectin-3 and soluble ST2, and their changes, with echocardiographic parameters and development of heart failure after ST-segment elevation myocardial infarction.

Presentation

Carcinoid heart disease

Presentation

Influence of galectin-3 and soluble ST-2 on risk of death and heart failure hospitalization in patients after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

Presentation

Ischemic versus dilated cardiomyopathy - differences in clinical characteristics and prognosis depending on heart failure etiology.

$Heart failure with Mid-Range ejection fraction - clinical characteristics and in-hospital outcomes. Insights into novel enigma based on the results from the ESC-HF Registries.$

Presentation

Heart failure with Mid-Range ejection fraction - clinical characteristics and in-hospital outcomes. Insights into novel enigma based on the results from the ESC-HF Registries.

Presentation

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Explore sponsored resources

Doctor Agata Tyminska

Contributor content

Association of galectin-3 and soluble ST2, and their changes, with echocardiographic parameters and development of heart failure after ST-segment elevation myocardial infarction.

Carcinoid heart disease

Influence of galectin-3 and soluble ST-2 on risk of death and heart failure hospitalization in patients after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

Ischemic versus dilated cardiomyopathy - differences in clinical characteristics and prognosis depending on heart failure etiology.

Heart failure with Mid-Range ejection fraction - clinical characteristics and in-hospital outcomes. Insights into novel enigma based on the results from the ESC-HF Registries.

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

ESC 365 is supported by